CMS Finalizes 2027 Medicare Rule: Implications for Psychedelic Therapies

CMS 2027 Medicare Rule Sets Payment and Coverage Framework

The Centers for Medicare & Medicaid Services (CMS) finalized its annual rule for the 2027 Medicare Physician Fee Schedule and Part B drug payment policies on November 9, 2026 (Federal Register Docket 2026-22743). This rule establishes how Medicare will pay for physician services and drugs, including any new FDA-approved psychedelic-assisted therapies or psychedelic-derived medicines that may reach the market by 2027. While the rule does not mention psychedelics specifically, its provisions are the mechanism by which any such therapies would be classified, coded, and reimbursed under Medicare Part B.

Mechanisms of Coverage: Coding, Classification, and Payment Pathways

Medicare coverage and reimbursement for new therapies depend on how they are coded and classified in the Physician Fee Schedule (PFS) and Part B drug payment system. For psychedelic-assisted therapies—such as MDMA- or psilocybin-assisted psychotherapy—this means that CMS must assign billing codes for both the drug component and the associated clinical services. The 2027 rule continues CMS’s practice of updating codes and payment rates to reflect changes in medical practice and new FDA approvals.

For a psychedelic therapy to be reimbursed, it must have:

• FDA approval for a specific indication
• An assigned Healthcare Common Procedure Coding System (HCPCS) code for the drug
• Appropriate Current Procedural Terminology (CPT) codes for the psychotherapy or administration services
• Inclusion in the Medicare Part B drug payment methodology, typically based on Average Sales Price (ASP) plus a margin

Notably, the rule incorporates recent statutory changes from the Inflation Reduction Act of 2022 and the Consolidated Appropriations Act, 2026, which affect drug pricing, rebates, and coverage limitations. These changes could influence the economics of psychedelic therapies, especially if they are high-cost or require extensive clinical support.

Policy and Research Implications for Psychedelic Therapies

The finalized Medicare rule is a critical, if often overlooked, factor in the adoption of novel therapies. For psychedelic medicines, the rule’s approach to coding, coverage, and payment will determine whether providers can offer these treatments to Medicare beneficiaries—primarily older adults and people with disabilities—once FDA approval is granted. Without established codes and clear reimbursement, provider uptake is likely to be slow, regardless of clinical efficacy.

One insight often missed in public discussions is that CMS’s decisions on coverage and coding can lag behind FDA approval by months or even years, creating a gap in access. Stakeholders should prepare for this by engaging with CMS early in the approval process to advocate for timely code creation and coverage determinations. Additionally, the rule’s updates to the Quality Payment Program and interoperability requirements could shape how psychedelic therapies are documented and reported in clinical practice, affecting both clinical outcomes tracking and reimbursement.

Risks, Unknowns, and Potential Barriers

Key risks for psychedelic therapies under the 2027 Medicare rule include:

• Delayed coding and coverage: New therapies may face significant administrative delays before being billable under Medicare, even after FDA approval.
• Uncertain payment rates: If CMS sets payment rates too low, providers may not offer the therapy, limiting access for Medicare patients.
• Coverage restrictions: The rule allows for limitations based on statutory changes, which could restrict coverage to certain patient populations or settings.
• Complexity of service delivery: Psychedelic-assisted therapy often requires extensive clinical support, which may not be fully captured by existing CPT codes, leading to reimbursement gaps.

Another underappreciated failure mode is the risk that CMS may classify the psychotherapy component as experimental or not "reasonable and necessary," delaying or denying coverage even if the drug itself is approved. This distinction between drug and service coverage is especially salient for psychedelic-assisted modalities.

Looking Ahead: Preparing for Market Access and Reimbursement

The 2027 Medicare rule signals that psychedelic therapies approaching FDA approval must navigate a complex regulatory and reimbursement landscape before reaching broad clinical adoption. Stakeholders—including researchers, manufacturers, and provider organizations—should proactively engage with CMS, the American Medical Association (for CPT coding), and other relevant bodies to ensure timely and appropriate coding, coverage, and payment policies.

As psychedelic therapies move closer to regulatory approval, the annual Medicare rule will remain a critical lever for market access. Early engagement, data-driven advocacy, and careful attention to coding and documentation requirements will be essential to avoid delays and maximize patient access once these therapies are FDA-approved.

Byline: Dr. Alex Morgan, PhD (Health Policy Analyst). How we research: This article was reviewed for accuracy and completeness by Dr. Alex Morgan on 2026-11-10, referencing the official CMS rule and current Medicare policy documents.